123 related articles for article (PubMed ID: 33055589)
21. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
22. Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer.
Steffen T; Dietrich D; Schnider A; Kettelhack C; Huber O; Marti WR; Furrer M; Gloor B; Schiesser M; Thierstein S; Brauchli P; Ruhstaller T;
Ann Surg; 2019 Jan; 269(1):83-87. PubMed ID: 28742685
[TBL] [Abstract][Full Text] [Related]
23. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
[TBL] [Abstract][Full Text] [Related]
24. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
[TBL] [Abstract][Full Text] [Related]
26. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02).
Jost C; Binek J; Schuller JC; Bauerfeind P; Metzger U; Werth B; Knuchel J; Frossard JL; Bertschinger P; Brauchli P; Meyenberger C; Ruhstaller T
Gastrointest Endosc; 2010 Jun; 71(7):1114-21. PubMed ID: 20304399
[TBL] [Abstract][Full Text] [Related]
27. High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.
Fehr M; Hawle H; Hayoz S; Thuss-Patience P; Schacher S; Riera Knorrenschild J; Dürr D; Knoefel WT; Rumpold H; Bitzer M; Zweifel M; Samaras P; Mey U; Küng M; Winterhalder R; Eisterer W; Hess V; Gérard MA; Templeton A; Stahl M; Ruhstaller T; ; ; ;
BMC Cancer; 2020 Feb; 20(1):166. PubMed ID: 32111181
[TBL] [Abstract][Full Text] [Related]
28. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
[TBL] [Abstract][Full Text] [Related]
29. An audit of surgical outcomes of esophageal squamous cell carcinoma.
Goan YG; Chang HC; Hsu HK; Chou YP
Eur J Cardiothorac Surg; 2007 Mar; 31(3):536-44. PubMed ID: 17222561
[TBL] [Abstract][Full Text] [Related]
30. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).
Ruhstaller T; Pless M; Dietrich D; Kranzbuehler H; von Moos R; Moosmann P; Montemurro M; Schneider PM; Rauch D; Gautschi O; Mingrone W; Widmer L; Inauen R; Brauchli P; Hess V
J Clin Oncol; 2011 Feb; 29(6):626-31. PubMed ID: 21205757
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
Yamagata Y; Saito K; Hirano K; Oya M
World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
[TBL] [Abstract][Full Text] [Related]
32. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
33. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
Prenzel KL; König A; Schneider PM; Schnickmann C; Baldus SE; Schröder W; Bollschweiler E; Dienes HP; Mueller RP; Izbicki JR; Hölscher AH
Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of robotic-assisted transhiatal esophagectomy for esophageal cancer after neoadjuvant chemoradiation.
Coker AM; Barajas-Gamboa JS; Cheverie J; Jacobsen GR; Sandler BJ; Talamini MA; Bouvet M; Horgan S
J Laparoendosc Adv Surg Tech A; 2014 Feb; 24(2):89-94. PubMed ID: 24401141
[TBL] [Abstract][Full Text] [Related]
35. Thoracoscopic esophagectomy with extended lymph node dissection in the left lateral position: technical feasibility and oncologic outcomes.
Ninomiya I; Osugi H; Fujimura T; Fushida S; Okamoto K; Maruzen S; Oyama K; Kinoshita J; Tsukada T; Kitagawa H; Takamura H; Nakagawara H; Tajima H; Hayashi H; Makino I; Ohta T
Dis Esophagus; 2014; 27(2):159-67. PubMed ID: 23551804
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
[TBL] [Abstract][Full Text] [Related]
37. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
38. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
39. Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.
Vincent J; Mariette C; Pezet D; Huet E; Bonnetain F; Bouché O; Conroy T; Roullet B; Seitz JF; Herr JP; Di Fiore F; Jouve JL; Bedenne L;
Eur J Cancer; 2015 Sep; 51(13):1683-93. PubMed ID: 26163097
[TBL] [Abstract][Full Text] [Related]
40. Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.
Phillips AW; Lagarde SM; Navidi M; Disep B; Griffin SM
Ann Surg; 2017 Apr; 265(4):750-756. PubMed ID: 27467444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
